Skip to main
BIIB

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 30%
Buy 17%
Hold 48%
Sell 4%
Strong Sell 0%

Bulls say

Biogen demonstrates a positive financial outlook, primarily driven by its robust portfolio of neurodegenerative treatments and strategic collaborations, with its multiple sclerosis franchise still contributing 40% of total revenue in 2025. The performance of Leqembi, which commands over 60% market share in the expanding anti-amyloid sector, reflects steady sequential growth, and its differentiated administration flexibility enhances its competitive position. Additionally, the successful launch of Zurzuvae is evident, with revenue surpassing expectations at approximately $65.7 million in 4Q25, underlining strong demand and reinforcing confidence in Biogen's market trajectory.

Bears say

Biogen's stock outlook is negatively influenced by anticipated declines in total revenue, projected to decrease by about $500 million in FY26, largely due to mounting competition and pressure on its multiple sclerosis franchise, which was crucial in contributing 40% of total revenue in 2025. The company has also issued non-GAAP EPS guidance for FY26 that falls below consensus expectations, indicating potential challenges in meeting financial targets amidst a competitive landscape. Furthermore, slower-than-expected growth of newer products like Leqembi, Skyclarys, and Zurzuvae adds to concerns regarding revenue sustainability and emphasizes the absence of immediate revenue drivers as critical risks moving forward.

Biogen (BIIB) has been analyzed by 23 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 17% recommend Buy, 48% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 23 analysts, Biogen (BIIB) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $198.52, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $198.52, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.